ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1753

Human T-Cells Express RANKL in Response to Combination of ZAP-70, Calcineurin and Voltage-Gated K+-Channel Signaling Following Co-Ligation of the Adhesion Molecule CD2 and the T-Cell Receptor Complex

Bohdan P. Harvey and Zehra Kaymakcalan, Biologics, AbbVie Bioresearch Center, Worcester, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Synovial Immune Biology, T cells and osteoclastogenesis

  • Tweet
  • Email
  • Print
Session Information

Title: T cell Biology in Rheumatoid Arthritis and Other Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Human T lymphocytes promote osteolysis in rheumatic diseases through the production of the osteoclastogenic cytokine RANKL.  We have previously demonstrated that RANKL secretion is mediated by the simultaneous engagement of the lymphocyte function-associated antigen 2 (CD2) and T-cell receptor (TCR/CD3).  However, the cell signaling events involved in its expression and release from T-cells are poorly understood.  By using a variety of signaling mutants of Jurkat as well as chemical inhibitors to cell signaling factors, we sought to elucidate the role of the TCR signaling complex and that of ion channel-mediated signaling cascades in the induction of RANKL by CD2.

Methods

The human T-cell line Jurkat and several signaling mutant derivatives were exposed to various combinations of bead bound anti-CD3, CD2 and CD28 antibodies. Total soluble RANKL was determined by osteoprotegrin capture sandwich ELISA.  A Jurkat clone with a stably integrated NFAT-luciferase reporter (NFAT-Luc) was used to assess the signaling events leading to NFAT activation, a known regulator of RANKL expression, in response to cross-linking of CD3, CD2 and CD28 for 4 hrs.  Prior to being exposed to the bead-bound antibodies, these cells were treated with a panel of chemical inhibitors to a variety of signaling factors including kinases (PI3K, CaMKII, AKT and PKC), phosphatase (calcineurin), calmodulin (CaM), calcium (TRPC3) and potassium ion channels (Kv1.1, 1.2 and 1.5) at broad concentration ranges.  Cytotoxicity was evaluated by CellTiterFluor®.

Results

Similar to primary human T lymphocytes, Jurkat cells secreted RANKL only in response to cross-linking of both CD2 and CD3.  This process was dependent on ZAP70 signaling but was independent of the following components associated with TCR signaling: beta-chain of the TCR, CD45, and PLCgamma.  Cross-linking of CD3 and CD28 failed to induce RANKL secretion in wild-type cells even though high levels of IL-2 were generated.  A 2-fold higher level of NFAT-Luc activation was observed with CD2/CD3 co-ligation as compared to CD28/CD3 and from the panel of inhibitors, chlorpromazine HCl, an inhibitor of both calmodulin and K+-channel signaling, was more effective at blocking NFAT-Luc activation by CD2/CD3 co-ligation than that of CD28/CD3, suggesting that these signaling cascades contribute to RANKL expression regulated by NFAT in response to CD2.  Additional inhibitors to either calcium or potassium signaling cascades (FK 506, a calcineurin inhibitor, and 4-aminopyridine, a Kv1.1 & 1.2 inhibitor, respectively) also blocked CD2/CD3-induced activation of the NFAT reporter without cytotoxicity; however, inhibition was not restricted to CD2 since CD28/CD3-induced signaling was also affected. 

Conclusion

Our results demonstrate that T-cells secrete RANKL in a ZAP70-dependent manner and only require the co-ligation of CD3 and CD2 in the absence of the co-stimulatory receptor CD28.  Furthermore, calcineurin and voltage-gated K+-channel signaling cascades were shown to induce the activation of NFAT in response to CD2/CD3 co-ligation, suggesting that these pathways may contribute to the expression RANKL in the inflamed RA synovium by T-cells.


Disclosure:

B. P. Harvey,

AbbVie Inc,

3,

AbbVie Inc,

1;

Z. Kaymakcalan,

AbbVie Inc,

3,

AbbVie Inc,

1.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/human-t-cells-express-rankl-in-response-to-combination-of-zap-70-calcineurin-and-voltage-gated-k-channel-signaling-following-co-ligation-of-the-adhesion-molecule-cd2-and-the-t-cell-receptor-complex/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology